200,000+ products from a single source!
sales@angenechem.com
Home > Quinoline > 189362-06-9
189362-06-9 | Urea,N-cyclopropyl-N'-[3-[(1,2-dihydro-2-oxo-6-quinolinyl)oxy]propyl]-N-[(1R,2R)-2-hydroxycyclohexyl]-
CAS No: 189362-06-9 Catalog No: AG00I2S4 MDL No:
Product Description
Catalog Number:
AG00I2S4
Chemical Name:
Urea,N-cyclopropyl-N'-[3-[(1,2-dihydro-2-oxo-6-quinolinyl)oxy]propyl]-N-[(1R,2R)-2-hydroxycyclohexyl]-
CAS Number:
189362-06-9
Molecular Formula:
C22H29N3O4
Molecular Weight:
399.4834
IUPAC Name:
1-cyclopropyl-1-[(1R,2R)-2-hydroxycyclohexyl]-3-[3-[(2-oxo-1H-quinolin-6-yl)oxy]propyl]urea
InChI:
InChI=1S/C22H29N3O4/c26-20-5-2-1-4-19(20)25(16-7-8-16)22(28)23-12-3-13-29-17-9-10-18-15(14-17)6-11-21(27)24-18/h6,9-11,14,16,19-20,26H,1-5,7-8,12-13H2,(H,23,28)(H,24,27)/t19-,20-/m1/s1
InChI Key:
ULGNGSQNNMKROG-WOJBJXKFSA-N
SMILES:
O[C@@H]1CCCC[C@H]1N(C(=O)NCCCOc1ccc2c(c1)ccc(=O)[nH]2)C1CC1
UNII:
J9J6NK6W4U
Properties
Complexity:
621
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
2
Defined Bond Stereocenter Count:
0
Exact Mass:
399.216g/mol
Formal Charge:
0
Heavy Atom Count:
29
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
399.491g/mol
Monoisotopic Mass:
399.216g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
90.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.2
Literature
| Title | Journal |
|---|---|
| K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models. | European journal of pharmacology 20120815 |
| A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease. | Atherosclerosis 20120301 |
| A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. | Journal of vascular surgery 20120201 |
| K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model. | PloS one 20120101 |
| Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation. | Thrombosis and haemostasis 20110301 |
| Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. | Trials 20110101 |
| Effects of cilostazol and k-134 on reconstructive surgery using prosthetic grafts in the abdominal aorta of beagle dogs. | Thrombosis research 20080101 |
| Investigation of binding proteins for anti-platelet agent K-134 by Drug-Western method. | Biochemical and biophysical research communications 20070223 |
| Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. | Biochemical pharmacology 20000215 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.